[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609576":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":63,"collaborators":7,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":7,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":7,"targetDuration":7,"studyType":75,"phases":7,"briefSummary":76,"conditions":77,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"KalVista Pharmaceuticals, Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Sebetralstat","Oral Plasma Kallikrein Inhibator",[14],"KVD900",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"KalVista Pharmaceuticals Ltd","CONTACT","1 (857) 999-0075","expandedaccess@kalvista.com",[22,36,45,54],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":7},"KalVista Investigative Site","AVAILABLE","Evansville","Indiana","47715","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-87.55585,37.97476,{"lat":34,"lon":33},{"facility":23,"status":24,"city":37,"state":38,"zip":39,"country":28,"countryCode":29,"cosmosGeoPoint":40,"geoPoint":44,"contacts":7},"Wheaton","Maryland","20902",{"type":31,"coordinates":41},[42,43],-77.05526,39.03983,{"lat":43,"lon":42},{"facility":23,"status":24,"city":46,"state":47,"zip":48,"country":28,"countryCode":29,"cosmosGeoPoint":49,"geoPoint":53,"contacts":7},"St Louis","Missouri","63110",{"type":31,"coordinates":50},[51,52],-90.19789,38.62727,{"lat":52,"lon":51},{"facility":23,"status":24,"city":55,"state":56,"zip":57,"country":28,"countryCode":29,"cosmosGeoPoint":58,"geoPoint":62,"contacts":7},"San Antonio","Texas","78229",{"type":31,"coordinates":59},[60,61],-98.49363,29.42412,{"lat":61,"lon":60},{"type":64,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100609576","treatment-of-angioedema-attacks-in-pediatric-ages-2-11-post-trial-and-naive-patients-with-hae-with-sebetralstat-100609576",false,"NCT07216378","Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat","On Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat","Inclusion Criteria:\n\n* Male or female patients 2 to 11 years of age.\n* Parent or LAR provides signed informed consent and patient provides assent (when applicable).\n* Confirmed diagnosis of HAE.\n\nExclusion Criteria:\n\n* Confirmed diagnosis of HAE with nC1-INH or acquired angioedema\n* Patient weighs \\\u003C9.5 kg\n* Patient participated in the KVD900-303 trial and withdrew prior to trial completion per the protocol or trial closure\n* Any clinically significant medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety.\n* Known hypersensitivity to sebetralstat or its excipients.\n* Patient with a medical history or known to have severe hepatic impairment (Child Pugh C).\n* Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.","ALL","2 Years","11 Years","EXPANDED_ACCESS","The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.",[78],"Hereditary Angioedema","2026-05-27",{"date":81,"type":82},"2026-05-28","ACTUAL",{"name":5,"class":6},4]